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SUMMARY
Background
Inﬂiximab is typically administered intravenously via 2- to 3-h duration
infusions. Infusions are time-consuming and costly. Shorter duration infu-
sions are administered at some centres. Limited safety data are available on
shorter duration infusions.
Aim
To determine risk of infusion reaction associated with standard 2- to 3-h
infusions vs. rapid infusions in patients receiving inﬂiximab therapy for
inﬂammatory bowel disease (IBD), rheumatoid arthritis, spondylarthopathy
and psoriatic disease.
Methods
MEDLINE, Embase, and Web of Science were searched. Inclusion required
human subjects, documentation of number of standard and rapid inﬂix-
imab infusions and number of incident infusion reactions. Studies of over-
lapping populations were excluded. Three reviewers independently
extracted data. Study quality was assessed. Relative risk (RR) was pooled
using random effects models.
Results
We identiﬁed 10 studies comprising 13 147 standard 2- to 3-h and 8497 ≤ 1-h
inﬂiximab infusions. Nine studies reported the risk of infusion reaction in
standard vs. 1-h infusions, demonstrating decreased RR of infusion reaction
with 1-h vs. standard infusions (0.9% vs. 2.2% of infusions; RR = 0.48,
P = 0.009). Seven studies limited to IBD also demonstrated decreased risk of
reaction (RR = 0.49, P = 0.002). Other comparisons demonstrated no differ-
ence in RR of reaction, including concomitant medication use (P = 0.30) or
analysis limited to high and medium quality studies (P = 0.07).
Conclusions
Rapid inﬂiximab infusions of ≤1-h duration are not associated with increased
risk of infusion reaction when compared to standard 2- to 3-h infusions in
selected patients who previously tolerated three to four standard infusions.
One-hour infusions will conserve health care resources and may lead to
improved adherence and quality of life in patients receiving inﬂiximab.
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INTRODUCTION
Inﬂiximab is a tumour necrosis factor-alpha inhibitor
that has decreased disease activity and improved quality
of life for adults and children with inﬂammatory bowel
disease (IBD) and other inﬂammatory conditions (rheu-
matoid arthritis, spondylarthropathy and psoriatic dis-
ease).1–5 Inﬂiximab is available only as an intravenous
preparation that is typically administered over 2–3 h.6, 7
Despite the beneﬁts of inﬂiximab, standard (2- to 3-h
duration) inﬂiximab infusion represents a signiﬁcant
burden in time away from school and/or work. In addi-
tion, routine inﬂiximab administration consumes valu-
able health care resources because space, time and staff
for infusion administration are limited and costly.8, 9
Infusion reactions associated with inﬂiximab adminis-
tration occur with 2–3% of infusions.10 Certain factors
may modify the risk of infusion reaction occurrence.
Patients receiving inﬂiximab maintain better disease con-
trol and have a lower risk of infusion reaction if inﬂix-
imab is routinely administered at a dosing interval of
8 weeks or less, rather than at intervals greater than
12 weeks.11, 12 Infusion reactions also occur less fre-
quently in patients receiving concomitant immunomodu-
lator therapy.13 Premedication with single dose steroid,
antihistamine, and/or acetaminophen just prior to the
infusion inconsistently demonstrates a decreased risk of
infusion reaction.14
Rapid (1-h or shorter duration) inﬂiximab infusions
have been implemented in few institutions.15–27 Limited
published data are available on the safety of rapid inﬂix-
imab infusions regarding the risk of infusion reaction.
To assess this risk, we performed a systematic review of
the literature and meta-analysis to identify studies of
infusion reaction occurrence associated with standard
inﬂiximab infusions compared to rapid infusions. We
aimed to determine if rapid 1-h duration inﬂiximab infu-
sions would be associated with increased risk of infusion
reaction compared with standard 2- to 3-h duration inf-
liximab infusions. We hypothesised that rapid inﬂiximab
infusions would not have greater risk of infusion reac-
tion compared with standard duration infusions.
MATERIALS AND METHODS
Search Strategies
We searched MEDLINE (Ovid Technologies, New York,
NY, USA), Embase (Elsevier, New York, NY, USA), and
ISI Web of Science (Thomson Reuters, New York, NY,
USA). All databases were searched from inception to 28
March 2013 according to the MOOSE guidelines.28
The MEDLINE search strategy used Medical Subject
Headings (US National Library of Medicine) and free
text words, and was as follows: [(‘exp Tumor Necrosis
Factor-alpha/Administration & Dosage, Adverse Effects,
Antagonists & Inhibitors, Drug Effects, Pharmacokinet-
ics, Pharmacology, Standards, Therapeutic Use, Toxicity’
or ‘inﬂiximab.mp’ or ‘remicade.mp’) and (‘infusion.mp’
or ‘exp Infusions, Intravenous/’) and (‘rate.mp’ or
‘administration rate.mp’ or ‘accelerated.mp’ or
‘rapid.mp’)], with results limited to humans.
The Embase search strategy was as follows: [(rapid or
rate or accelerat*) and (administr* or ‘infusion’ or ‘intra-
venous drug administration’) and (inﬂiximab or remi-
cade or ‘tumor necrosis factor alpha inhibitor’)], with
results limited to humans.
The ISI Web of Science search strategy was as follows:
[(rapid or rate or accelerat*) and (administr* or infusion
or intravenous or IV) and (inﬂiximab or remicade or
‘tumor necrosis factor alpha inhibitor*’ or ‘TNF-alpha
inhibitor*’)].
The search was not limited by language. We then
reviewed the bibliographies of included studies to iden-
tify any additional relevant studies.
Study Selection
Inclusion required documentation of human subjects,
number of standard and rapid inﬂiximab infusions and
number of infusion reactions that occurred in each
group. Studies were excluded if different durations of
infusions were not compared and/or adequately
described. We attempted to contact multiple authors to
obtain missing data. In studies with overlapping or
duplicate subject populations based on study location
and/or authorship, the most recent publication was
included. All others were excluded. Two independent
reviewers (HCN, MPR) read the titles and abstracts of
all studies identiﬁed in the search. Each reviewer applied
exclusion and inclusion criteria independently. The full
text of each study that was not excluded based on the
abstract alone was then reviewed. All discrepancies were
resolved by consensus with 100% consensus achieved.
Data Extraction
Three independent reviewers (HCN, MPR, JA) extracted
the following data from the included relevant studies:
author, publication year, type of control group, number
of patients, age range, underlying disease, concomitant
medication use, documentation of tolerance of or prior
infusion reaction to standard duration inﬂiximab infu-
sions, infusion duration, dosage, administration of single
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dose premedication just prior to the infusion, and num-
ber and type of infusion reactions (severity, delayed vs.
acute). All discrepancies were resolved by consensus with
100% consensus achieved.
Quality Assessment
We assessed the quality of the included studies using the
Newcastle-Ottawa quality scale for cohort studies.29 We
also included four relevant ad hoc quality criteria,
including the following: (i) peer review of the ﬁnal publi-
cation; (ii) documentation of use or non-use of concomi-
tant immunomodulators and/or steroids; (iii)
documentation of the use or non-use of single dose
premedication prior to infusions; and (iv) disclosure of
conﬂict of interest resulting from author–industry ﬁnan-
cial relationships.
Meta-analyses
The primary outcome measured (per-infusion analysis)
was the risk of infusion reaction following administration
of standard inﬂiximab infusions compared to 1-h infu-
sions where risk was calculated as the number of infu-
sion reactions per infusion administered in each
treatment arm. The primary outcome was also calculated
to determine the risk of infusion reaction per patient
with the analysis weighted by the number of infusions
administered to each patient in each treatment arm
(per-patient analysis).
Subgroup analyses were performed for additional out-
comes reported, including analyses of the risk of: (i)
infusion reaction in standard vs. 30- to 45-min inﬂix-
imab infusions; (ii) infusion reaction in all patients who
did or did not routinely receive premedication prior to
infusions comparing standard vs. 1-h infusions; (iii) infu-
sion reaction in patients who concomitantly received one
or more immunomodulator (including mercaptopurine,
methotrexate, azathioprine and/or leﬂunomide) and/or
oral steroids comparing standard vs. 1-h infusions; (iv)
severe infusion reaction with standard vs. 1-h infusions;
(v) delayed infusion reaction with standard vs. 1-h infu-
sions; (vi) infusion reaction in subgroups of patients with
IBD or in subgroups of patients with other inﬂammatory
conditions with standard vs. 1-h infusions; (vii) infusion
reaction in subgroups of patients receiving high dose
(5–10 mg/kg) vs. low dose (<5 mg/kg) inﬂiximab, each
comparing standard vs. 1-h infusions; and (viii) infusion
reaction limited to high and medium quality studies as
deﬁned by the Newcastle-Ottawa quality scale for cohort
studies. A priori prespeciﬁed subgroup analyses included
(ii), (iii) and (vi). After study selection and review,
post hoc subgroup analyses (i), (iv), (v), (vii) and (viii)
were added based on the available data in the studies.
All meta-analyses were completed in accordance with
preferred reporting items for systematic reviews and
meta-analyses (PRISMA) guidelines.30
Sensitivity Analyses
Sensitivity analyses were performed by three methods to
conﬁrm the stability of the per-infusion primary out-
come, the risk of infusion reaction following standard
inﬂiximab infusions compared to 1-h infusions. We re-
analysed the data by sequentially removing one study at
a time. We then compared studies with few (<2.5%)
infusion reactions to those with a greater proportion
(≥2.5%) of infusion reactions. We also compared studies
with small (<300), medium (300–1000), or large (>1000)
numbers of infusions.
Statistical Analyses
A bivariate random effects regression model meta-analysis
was performed with Stata 12.0 for Mac (StataCorp, College
Station, TX, USA). Heterogeneity of relative risks (RR)
across studies was evaluated with the Cochran’s Q statistic;
P < 0.10 represented signiﬁcant heterogeneity. The I2 sta-
tistic was also used to assess heterogeneity, with <25% rep-
resenting low heterogeneity and >75% representing high
heterogeneity. Assessment of publication bias was evalu-
ated with visual inspection of funnel plot.
RESULTS
Literature Search
Of the 1535 studies identiﬁed in the literature search, 13
studies were included in our ﬁnal analyses (Figure 1).
The authors of two studies that were initially excluded
due to lack of published data were contacted and pro-
vided additional data, so the studies were included in
our ﬁnal analyses.17, 21
Three studies met all inclusion and exclusion criteria
except that they included the number of patients receiving
standard and rapid inﬂiximab infusions rather than the
number of infusions.15, 17, 18 These studies were included
in the per-patient analysis of the primary outcome only
and in none of the other secondary meta-analyses. One
study could not be included in the per-patient analysis
because it included only infusion-level data.26 One addi-
tional study was not included in the per-patient analysis of
the primary outcome (standard infusions vs. 1-h infu-
sions) because it only included 30- to 45-min rapid infu-
sions.21 There was 100% agreement between reviewers
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(HCN, MPR) on selection of studies. Design of the
selected studies is summarised in Table 1.
Study Characteristics
The 10 studies with infusion-level data comprised
13 147 standard inﬂiximab infusions and 8497 rapid
infusions. Of the rapid infusions, there were 7294 infu-
sions of 1-h duration and 1203 infusions of 30- to
45-min duration. Selected study characteristics are sum-
marised in Table 2.
Quality Assessment
The quality assessment of all included studies is sum-
marised in Table 3. Seven of the studies were considered
to be of either medium or high quality.16, 20–23, 25, 27 Of
the 13 reviewed studies, four disclosed conﬂict of inter-
est.16, 17, 24, 27
Standard vs. 1-h Infusions
Infusion reactions occurred in 282 of 12 922 (2.2%)
standard inﬂiximab infusions and in 69 of 7294 (0.9%)
Ovid MEDLINE:
268 studies
Embase:
579 studies
Web of Science:
543 studies
Bibliographies:
145 studies
•Non-human:15
6 remaining 8 remaining
Excluded Excluded Excluded Excluded
Excluded
Lacked infusion-level data
18 remaining 20 remaining
26 duplicates removed
26 studies remaining
Studies included in final meta-analyses: 13
•Non-human:2 •Non-human:13
•Overlapping studies: 6
•Insufficient data: 7
•Provided missing data: 2*
•Included patient-level data: 3**
• Included in per-infusion analyses: 10
• Included in per-patient analysis: 11
•No infliximab rate
  change:247
•No infliximab rate
  change:569
•No infliximab rate
  change: 512
•No infliximab rate
  change: 125
Figure 1 | Study ﬂow diagram.
*The author of two excluded
studies provided additional
data, so they were included.
**Met all other inclusion and
exclusion criteria except for
infuion-level data. These were
included in per-patient
analysis of primary outcome
only.
Table 1 | Design of selected studies
Author, year (location)
Prospective vs.
retrospective?
Historical control vs.
true control? Cross-over? Peer reviewed?
Ba~nuelos-Ramırez, 2007 (Mexico) Prospective True control No Yes
Befrits, 2008 (unspeciﬁed) Prospective Historical control No No – Abstract
Belhassan, 2013 (France) Retrospective Historical control Yes Yes
Bhat, 2010 (Ireland) Retrospective Historical control Yes Yes
Breynaert, 2011 (Belgium) Retrospective Historical control Yes Yes
Buch, 2006 (England) Retrospective Historical control Yes Unclear – Letter to Editor
Clare, 2009 (England) Prospective Historical control Yes Yes
El Miedany, 2011 (England) Retrospective Unknown Unknown No – Abstract
Lee, 2011 (Canada) Prospective True control No Yes
Rojany, 2006 (unspeciﬁed) Retrospective Historical control No No – Abstract
Saxena, 2011 (unspeciﬁed) Prospective Historical control Yes No – Abstract
Shergy, 2002 (US) Prospective True control Yes Yes
Yeckes, 2009 (US) Retrospective Historical control Yes Yes
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Table 2 | Selected study characteristics
Author Age (years) Disease
Concomitant
medications
Routine
premedication
Inﬂiximab
dose
(mg/kg)
No. of
standard
infusions
prior to
starting
rapid
infusions
Duration of
rapid
inﬂiximab
infusions
tested
Subtypes
of infusion
reactions
studied
Ba~nuelos-
Ramırez
N/A RA, SA Some on MTX,
steroids*
None 1.5–3 0 30–45 min N/A
Befrits 37
(median)
IBD, SA Some on AZA,
steroids*
N/A N/A 4 1 h N/A
Belhassan 16–89
(range)
IBD Some on AZA,
MTX, steroids*
All received
IV HC
5–10 3 1 h Acute
mild,
acute
severe,
delayed
Bhat N/A IBD Some on AZA,
MTX, and/or MP*
All received
PO loratidine;
IV HC in
subset of
patients*
5 4 1 h, 30 min Delayed,
severe
Breynaert 40
(median)
IBD Some on AZA,
MTX, MP, and/or
steroids*
IV HC and CZ
in speciﬁed
subset
of patients
5 4 1 h Delayed,
severe
Buch 22–77
(range)
RA, SA, PA All on MTX and/or
leﬂunomide
Some received
IV HC
and CP*
3–5 4 1 h, 30 min Severe
Clare 14–91
(range)
IBD Some on AZA,
MTX, MP, MMF,
and/or steroids*
Some received
IV HC
and/or CP*
5–10 4 1 h, 30 min Delayed,
severe
El Miedany 23–78
(range)
RA, SA All on DMARD,
mainly MTX,
SZA, leﬂunomide
Some received
IV HC and
antihistamine*
N/A 4 1 h Mild,
moderate,
delayed
Lee N/A IBD, RA, SA,
psoriasis
AZA, MTX,
and/or MP
IV HC in
speciﬁed subset
of patients
3–5 3 1 h N/A
Rojany Adult IBD Some on
unspeciﬁed
immunomodulators*
N/A N/A 4 1 h Delayed,
severe
Saxena N/A IBD N/A All received
premedication,
but medication
not speciﬁed
N/A 4 1 h, 30 min Severe
Shergy ≥18 RA All on MTX;
some on steroids
and/or unspeciﬁed
DMARDs
N/A 3 4 1 h N/A
Yeckes 12–21
(range)
IBD All on AZA, MTX,
and/or MP
Some received
DP and
IV MP*
5–10 3–4 1 h Severe
N/A, data not available; RA, rheumatoid arthritis; SA, spondylarthropathy; IBD, inﬂammatory bowel disease; PA, psoriatic arthritis;
MTX, methotrexate; AZA, azathioprine; MP, mercaptopurine; DMARD, disease-modifying antirheumatic drug; MMF, mycopheno-
late; HC, hydrocortisone; MP, methylprednisolone; DP, diphenhydramine; CP, chlorpheniramine; CZ, cetirizine; IFX, inﬂiximab; PO,
oral; IV, intravenous.
* Not speciﬁed which patients received medication.
Aliment Pharmacol Ther 2013; 38: 365-376 369
ª 2013 John Wiley & Sons Ltd
Meta-analysis: rapid inﬂiximab infusions are safe
1-h infusions. Meta-analysis of per-infusion data across
nine studies demonstrated decreased risk of infusion
reaction with 1-h infusions compared to standard infu-
sions with a RR of 0.48 [95% conﬁdence interval (CI)
0.28–0.83; P = 0.009] (Figure 2a). There was moderate
evidence of heterogeneity between studies (I2 = 61.2%;
Cochran’s Q 17.8, P = 0.01). There was little evidence of
publication bias as demonstrated by visual inspection of
the funnel plot (see Figure S1).
Eleven studies included the number of infusion reac-
tions per patient in standard vs. 1-h infusions. A total of
181 of 2074 patients (8.7%) receiving standard infusions
and 95 of 1422 patients (6.7%) receiving 1-h infusions
experienced an infusion reaction. Meta-analysis of per-pa-
tient data also demonstrated decreased risk of infusion
reaction with 1-h infusions compared to standard infu-
sions with a RR of 0.45 (95% CI 0.25–0.80; P = 0.007)
(Figure 2b). There was signiﬁcant evidence of hetero-
geneity between studies (I2 = 87.1%; Cochran’s Q 32.1,
P = 0.002). The funnel plot (see Figure S2) was asymmet-
rical. It is notable that the smaller studies produced smal-
ler effect sizes, resulting in a bias towards the null effect.
Standard vs. 30- to 45-min Infusions
Infusion reactions occurred in 59 of 1807 (3.3%) standard
inﬂiximab infusions and in 13 of 1203 (1.1%) infusions of
30- to 45-min duration. Four of the studies19, 22, 24, 25
used a 30-min infusion protocol; one of the studies used a
30-min infusion protocol.21 Meta-analysis of per-infusion
data demonstrated no signiﬁcant difference in risk of infu-
sion reaction between the groups (RR = 0.48, 95% CI
0.10–2.27; P = 0.35). There was moderate evidence of het-
erogeneity between studies (I2 = 58.8%; Cochran’s Q 7.3;
P = 0.06) (Figure 3).
Premedication Administration
Premedication use was inadequately documented or
inconsistently administered across most studies
(Table 2). Only four studies provided clear documenta-
tion of consistent administration or non-administration
of premedication.16, 21, 23, 26
In the study by Belhassan et al., premedication with
200 mg IV hydrocortisone was given prior to all infu-
sions, both standard and 1-h duration.16 Lee et al.
described distinct groups of patients who consistently
received premedication with corticosteroids.26 The RR of
infusion reaction with standard vs. 1-h infusion with
consistent premedication administration was 0.65 (95%
CI 0.28–1.50; P = 0.31) (see Figure S3).
In the study by Breynaert et al., no premedication was
given prior to any infusion for patients in the 1-h infu-
sion group.23 Patients in the standard infusion group
received premedication if they had a prior infusion reac-
tion or if they had a prolonged dosing interval greater
than 13 weeks. Therefore, no comparable data were
available for rate of infusion reaction in patients who
exclusively received no premedication with both standard
and 1-h infusions.
Table 3 | Assessment of study quality using Newcastle-Ottawa quality scale for cohort studies and ad hoc quality
criteria
Author
Selection Comparability
Outcome
assessment Global NOQS
assessment
Ad hoc criteria
1 2 3 4 1 2 1 2 3 1 2 3 4
Ba~nuelos-Ramırez * * * * * * * * * HQ * * *
Befrits * * * * * LQ *
Belhassan * * * * * * * MQ * * * *
Bhat * * * * * * * MQ * * *
Breynaert * * * * * * * MQ * * *
Buch * * * * * LQ * * * *
Clare * * * * * * * MQ * * *
El Miedany * * * * * * LQ * * *
Lee * * * * * * LQ * * *
Rojany * * * * * * LQ
Saxena * * * * * * LQ *
Shergy * * * * * * * MQ * *
Yeckes * * * * * * * MQ * * * *
NOQS, Newcastle-Ottawa quality scale; HQ, high quality (nine stars); MQ, medium quality (seven or eight stars); LQ, low quality
(ﬁve or six stars); VLQ, very low quality (four stars or less).
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In the six remaining studies in which premedication
was inadequately documented or inconsistently adminis-
tered, the pooled risk of infusion reaction was not different
from that of those studies in which all patients received
premedication prior to infusions (RR = 0.49, 95% CI
0.19–1.17; P = 0.11) (see Figure S4).19, 20, 22, 24, 25, 27
NOTE: Weights are from random effects analysis
Overall  (I2 = 61.2%, P = 0.012)
Yeckes
Belhassan
Saxena
Author
Buch
Breynaert
Lee
Clare
Shergy
Bhat
2009
2012
2011
Year
2005
2011
2011
2009
2002
2010
IBD
IBD
IBD
Disease
Arthritis
IBD
Mixed
IBD
Arthritis
IBD
0.48 (0.28, 0.83)
0.89 (0.09, 8.33)
0.75 (0.30, 1.90)
(Excluded)
risk (95% CI)
0.13 (0.04, 0.44)
0.35 (0.24, 0.51)
0.29 (0.04, 2.18)
0.71 (0.36, 1.41)
1.05 (0.56, 1.95)
Relative
0.08 (0.00, 1.28)
69/7294
1/50
6/989
0/3
3/796
33/4307
1/274
14/376
11/380
Events,
0/119
282/12922
3/133
17/2102
0/87
Standard
24/845
107/4848
17/1356
18/344
80/2901
Events,
16/306
100.00
4.77
14.67
0.00
Weight
11.42
22.73
5.66
18.27
19.23
%
3.26
1−h
Test of overall effect: Z = 2.62 (P = 0.009)
Favours 1−hour infusion Favours standard infusion 
1.01 .1 10
Overall  (I2 = 87.1%, P = 0.000)
Befrits
Buch
Clare
Bhat
El Miedany
Saxena
Rojany
Yeckes
Author
Breynaert
Belhassan
Shergy
2008
2005
2009
2010
2011
2011
2006
2009
Year
2011
2012
2002
IBD
Arthritis
IBD
IBD
Arthritis
IBD
IBD
IBD
Disease
IBD
IBD
Arthritis
0.45 (0.25, 0.80)
1.44 (0.53, 3.95)
0.17 (0.05, 0.56)
0.30 (0.03, 2.92)
0.08 (0.01, 1.36)
1.84 (1.23, 2.74)
(Excluded)
1.27 (0.64, 2.52)
0.33 (0.04, 2.85)
risk (95% CI)
0.72 (0.34, 1.54)
0.17 (0.02, 1.26)
0.60 (0.33, 1.10)
Relative
95/1422
10/68
3/171
1/376
0/24
43/112
0/15
14/49
1/15
10/340
1/55
12/197
Events,
181/2074
5/49
24/234
3/344
16/69
29/139
0/13
11/49
3/15
Standard
19/468
17/161
54/533
Events,
100.00
0.60
9.92
4.35
2.57
0.60
0.64
4.42
1.11
Weight
55.36
18.69
2.36
%
1−h
Test of overall effect: Z = 2.70 (P = 0.007)NOTE: Weights are from number of infusions
Favours 1−h infusion Favours standard infusion 
1.01 .1 10
(b)
(a)
Figure 2 | Infusion reactions in standard vs. 1-h inﬂiximab infusions. Results of (a) per-infusion analysis and (b) per-
patient analysis. IBD, inﬂammatory bowel disease.
NOTE: Weights are from random effects analysis
Overall  (I2 = 58.8%, P = 0.063)
Clare
Bhat
Bañuelos−Ramírez
Saxena
Buch
Author
2009
2010
2007
2011
2005
Year
IBD
IBD
Arthritis
IBD
Arthritis
Disease
0.48 (0.10, 2.27)
0.45 (0.21, 0.96)
0.78 (0.05, 12.17)
3.00 (0.31, 28.62)
(Excluded)
0.03 (0.00, 0.54)
risk (95% CI)
13/1203
10/426
0/11
3/225
0/16
0/525
≤45−min
Events,
59/1807
18/344
16/306
1/225
0/87
24/845
Standard
Events,
100.00
40.15
18.60
23.00
0.00
18.26
Weight
%Relative
Test of overall effect: Z = 093 (P = 0.35)
Favours ≤45−min infusion Favours standard infusion
1.01 .1 10
Figure 3 | Infusion reactions in standard vs. 30- to 45-min inﬂiximab infusions.
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In the study by Ba~nuelos-Ramırez et al., no premedica-
tion was administered with any inﬂiximab infusion, either
standard or 30- to 45-min infusions, throughout the
course of the study.21 The RR of infusion reaction in this
study without premedication (RR = 3.0, 95% CI 0.31–
28.6; P = 0.34) was not substantially different from the RR
of infusion reaction in meta-analysis of the four stud-
ies19, 22, 24, 25 that included 30-min inﬂiximab infusions
in which premedication was inadequately documented or
inconsistently administered (RR = 0.28, 95% CI 0.05–
1.64; P = 0.16).
Concomitant Medication Therapy
In patients who received concomitant immune suppress-
ing medications along with inﬂiximab, infusion reactions
occurred in 96 of 3205 (3.0%) standard inﬂiximab infu-
sions and in 16 of 1255 (1.3%) 1-h infusions. Concomi-
tant immune suppressing therapies included one or
more immunomodulator (mercaptopurine, methotrexate,
azathioprine, or leﬂunomide) and/or ongoing oral steroid
therapy (Table 2); the four studies included in the analy-
sis were those in which all patients were clearly receiving
at least one concomitant medication. Meta-analysis of
per-infusion data demonstrated no signiﬁcant difference
in risk of infusion reaction between standard inﬂiximab
infusions and 1-h infusions (RR = 0.53, 95% CI 0.16–
1.72; P = 0.29) (Figure 4). There was moderate evidence
of heterogeneity between studies (I2 = 65.9%; Cochran’s
Q 8.8; P = 0.03). There were insufﬁcient data to make
comparisons between different concomitant medications.
Infusion Reaction Types
Severe infusion reactions occurred in 18 of 6413 (0.3%)
standard inﬂiximab infusions and in 2 of 5602 (0.04%)
1-h infusions. Meta-analysis of per-infusion data across
six studies demonstrated no signiﬁcant difference in
risk of severe infusion reaction between the groups
(RR = 0.33, 95% CI 0.06–1.83; P = 0.20) (see Figure
S5). There was moderate evidence of heterogeneity
between studies (I2 = 38.7%; Cochran’s Q 4.9;
P = 0.18).
Delayed infusion reactions occurred in 39 of 5396 (0.7%)
standard inﬂiximab infusions and in 8 of 4763 (0.2%) 1-h
inﬂiximab infusions. Meta-analysis of per-infusion data
across three studies showed decreased risk of delayed infu-
sion reaction with 1-h inﬂiximab infusions vs. standard infu-
sions (RR = 0.27, 95% CI 0.13–0.58; P = 0.001) (see Figure
S6). There was minimal evidence of heterogeneity between
studies (I2 = 0%; Cochran’s Q 0.35; P = 0.84).
Primary Disease
In seven studies with data limited to subgroups of patients
with IBD, infusion reactions occurred in 172 of 8003
(2.1%) standard inﬂiximab infusions and in 55 of 5874
(0.9%) 1-h infusions. Meta-analysis of per-infusion data
demonstrated decreased risk of infusion reaction with 1-h
infusions (RR = 0.49, 95% CI 0.31–0.76; P = 0.002)
(Figure 5). There was evidence of heterogeneity between
studies (I2 = 24.6%; Cochran’s Q 17.8; P = 0.01).
Four studies included data limited to subgroups of
patients with other inﬂammatory conditions. One study
did not provide data regarding 1-h inﬂiximab infu-
sions.21 Of the remaining three studies, infusion reac-
tions occurred in 111 of 5144 (2.2%) standard inﬂiximab
infusions and in 14 of 1420 (1.0%) 1-h infusions.20, 24, 26
Meta-analysis of per-infusion data demonstrated no sig-
niﬁcant difference in risk of infusion reaction between
the groups (RR = 0.40, 95% CI 0.07–2.11; P = 0.28) (see
NOTE: Weights are from random effects analysis
Overall  (I2 = 65.9%, P = 0.032)
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Buch
Lee
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Yeckes
Year
2005
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2009
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Arthritis
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0.53 (0.16, 1.72)
Relative
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0.13 (0.04, 0.44)
0.95 (0.11, 8.19)
0.94 (0.50, 1.77)
0.89 (0.09, 8.33)
16/1255
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1−h
3/796
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11/379
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4/114
65/2113
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Favours 1−h infusion Favours standard infusion 
1.01 .1 10
Figure 4 | Infusion reactions in standard vs. 1-h inﬂiximab infusions with concomitant immunomodulator medications.
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Figure S7), with signiﬁcant heterogeneity between studies
(I2 = 79.7%; Cochran’s Q 9.8; P = 0.008).
Inﬂiximab Dosing
Five studies included data regarding high dose (5–
10 mg/kg) inﬂiximab16, 22, 23, 25, 27 with which infusion
reactions occurred in 161 of 7733 (2.1%) standard inﬂix-
imab infusions and in 54 of 5841 (0.9%) 1-h infusions.
Meta-analysis of per-infusion data demonstrated
decreased risk of infusion reaction with 1-h infusions
(RR = 0.50, 95% CI 0.30–0.84; P = 0.008) (see Figure
S8). There was little evidence of heterogeneity between
studies (I2 = 39.2%; Cochran’s Q 6.44; P = 0.17).
Two studies contained data regarding low dose
(<5 mg/kg) inﬂiximab.20, 26 Meta-analysis of per-infusion
data demonstrated no signiﬁcant difference in risk of
infusion reaction with 1-h infusions (RR = 1.00, 95% CI
0.55–1.84; P = 1.00).
Quality of Studies
Seven studies were classiﬁed as either high or medium
quality as deﬁned by the Newcastle-Ottawa quality scale
(Table 3). Six of these studies contained data comparing
risk of infusion reaction in standard inﬂiximab infusions
to 1-h infusions.16, 20, 22, 23, 25, 27 One high-quality study
included only data on 30- to 45-min infusions.21
Of the six high and medium quality studies containing
data about 1-h infusions, meta-analysis of per-infusion
data demonstrated no difference in the risk of infusion
reaction (RR = 0.60, 95% CI 0.35–1.04; P = 0.07)
between standard infusions (241 reactions of 10 634
infusions; 2.3%) and 1-h infusions (65 reactions of 6221
infusions; 1.0%). There was moderate evidence of hetero-
geneity between studies (I2 = 60.7%; Cochran’s Q 12.5;
P = 0.03).
Of the three high and medium quality studies contain-
ing data about 30- to 45-min inﬂiximab infu-
sions,21, 22, 25 meta-analysis of per-infusion data
demonstrated no difference in the risk of infusion reac-
tion (P = 0.44) between standard infusions (35 reactions
of 875 infusions; 4.0%) and 30- to 45-min infusions (13
reactions of 662 infusions; 2.0%). There was minimal
evidence of heterogeneity between the studies
(I2 = 20.7%; Cochran’s Q 2.57; P = 0.28).
Sensitivity Analysis
Using sequential study-by-study removal, at each
re-analysis of the primary outcome, the lower risk of
infusion reaction with 1-h inﬂiximab infusions compared
to standard infusions persisted with one exception23;
with removal of the study by Breynaert et al., no signiﬁ-
cant difference between the risk of infusion reaction in
standard vs. 1-h inﬂiximab infusions was demonstrated
(RR = 0.46, 95% CI 0.20–1.03; P = 0.06). Thus, with
sequential removal of individual studies, none of the
analyses demonstrated greater risk for rapid infusions
compared with standard infusions.
To assess the possible inﬂuence of differing baseline risk
of infusion reaction in different patient populations across
studies, we compared studies documenting few (<2.5%)
infusion reactions with standard infusions16, 19, 23, 26, 27
to those with greater incidence (≥2.5%) of infusion reac-
tions.20, 22, 24, 25 When analysed regarding the primary
outcome, studies with fewer infusion reactions with stan-
dard infusions had even fewer infusion reactions with 1-h
infusions (RR = 0.39, 95% CI 0.28–0.56, P < 0.001) than
NOTE: Weights are from random effects analysis
Overall  (I2 = 24.6%, P = 0.250)
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Figure 5 | Infusion reactions in standard vs. 1-h inﬂiximab infusions in patients with inﬂammatory bowel disease.
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studies with greater proportions of infusion reactions with
standard infusions (RR = 0.43, CI 0.16–1.19, P = 0.10).
When groups of studies of different sizes were assessed,
there was no difference in the risk of infusion reaction
between small studies of <300 total infusions19, 21, 27
(RR = 0.89, CI 0.09–8.33; P = 0.92), medium-sized stud-
ies of 300–1000 infusions22, 24, 25 (RR = 0.25, CI 0.06–
1.16; P = 0.08), and large studies of >1000 infu-
sions16, 20, 23, 26 (RR = 0.58, CI 0.29–1.16; P = 0.12). In
no method of these sensitivity analyses were results con-
tradictory to the primary outcome of our meta-analysis,
conﬁrming its stability. One-hour inﬂiximab infusions
remained non-inferior to standard infusions regarding risk
of infusion reaction.
DISCUSSION
This study demonstrated that rapid inﬂiximab infusions
of 1-h or shorter duration, in selected patients who pre-
viously tolerated a minimum of three standard duration
infusions, are not associated with an increased risk of
infusion reaction when compared to the risk of reaction
with standard 2- to 3-h duration infusions in the general
population of unselected patients. In fact, a signiﬁcantly
lower risk of infusion reaction was found with shorter
duration infusions. This was consistent when analysed
both on a per-infusion and per-patient basis. We per-
formed multiple subgroup analyses, each of which failed
to demonstrate greater risk of infusion reaction with
rapid infusions in selected patients who previously toler-
ated at least three standard infusions.
Limitations of Study
This study was limited by the common problems encoun-
tered in literature reviews. Relevant studies often included
incomplete data, varying sources of bias and confounding
variables that were difﬁcult to account for. In the studies
that did clearly deﬁne infusion reactions as ‘severe’, ‘acute’,
or ‘delayed’, where these data were used for subgroup
analyses, the deﬁnitions of these terms varied somewhat
from study to study, making the results of these analyses
less reliable. The majority of the studies were retrospective
with historical control populations that mainly consisted
of the same patients that subsequently entered rapid inﬂix-
imab protocols. This introduces potential bias that limits
our conﬁdence in the apparent superiority of rapid infu-
sions over standard infusions in selected patients who pre-
viously tolerated at least three standard infusions.
None of the studies were designed to blind patients to
the rate of infusion. Although this may have introduced
the possibility of misclassifying symptoms as infusion
reactions, we postulate that this would tend to overesti-
mate the number of infusion reactions. Premedicating
patients prior to inﬂiximab infusion with single dose
antihistamine and/or steroid was one other potentially
important confounding variable that may have modiﬁed
the risk of infusion reaction. We were unable to account
for this inﬂuence because the majority of studies did not
document which patients received premedication. Fur-
thermore, in many studies, patient attrition was not
accounted for and could introduce a potential source of
bias if patients preferentially left one group due to
undocumented infusion reactions.
There is also the possibility that prior exposure to
other biological agents or other immune suppressing
medications may alter the likelihood of formation of
antibodies to inﬂiximab (ATI) or of infusion reactions.
However, none of the papers identiﬁed in this search
addressed prior medication usage or measured ATI.
Our use of infusion-level data rather than patient-
level data for this meta-analysis may lead to over- or
under-conﬁdence in the role infusion duration plays in
infusion reactions. This may happen if an individual
patient has a predisposition to infusion reaction, leading
to an increased likelihood of reactions in all infusions
for that given patient. Conversely, a patient who is on
concomitant immunomodulator medication may have a
lower incidence of infusion reaction. Thus, patient pre-
disposition may dominate over patient-to-patient differ-
ences in infusion reaction. For this reason, we explored
numerous post hoc subgroup analyses in our study.
Despite the above limitations, our meta-analysis sufﬁ-
ciently demonstrated the safety of rapid inﬂiximab infu-
sions with regard to infusion reactions.
Implications of Study
Rapid inﬂiximab infusions may result in health care
resource conservation. A recent study of a commercial
US claims database showed that the average cost of
administering inﬂiximab for rheumatoid arthritis, includ-
ing the cost of time spent monitoring the infusion, was
8.7% of the total cost of the drug.8 In a Canadian study,
changing a patient from a 2-h inﬂiximab infusion with a
30-min post infusion observation period to a 1-h infu-
sion without an observation period led to a cost saving
of 60% in fees related to administration of the medica-
tion.26 In our institution, the average cost per infusion
for administration of 300 mg inﬂiximab infused over 2 h
without a post infusion observation period is US $7323.
Of this cost, US $858 (11.7%) is accrued due to drug
administration and monitoring. If the infusion duration
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of each dose was reduced from 2 to 1 h, we estimate a
cost saving of US $317 per infusion, reducing the cost of
administration by 37% per infusion. This would lead to
a cost savings of US $2140 per patient per year for the
standard protocol of infusions given every 8 weeks. In
addition, rapid infusions would liberate space and health
care staff in institutions with limited resources to accom-
modate more patients.
Rapid inﬂiximab infusions are likely to be more conve-
nient for patients, which may lead to improved adherence.
Non-adherence with inﬂiximab in the ﬁrst year of therapy
occurs in 25–35% of adults with Crohn’s disease and is
associated with substantially increased medical costs and
rate of hospitalisations when compared to patients who
are adherent with inﬂiximab infusions.31, 32 Therefore, if
adherence were improved with rapid inﬂiximab infusions,
this would further reduce medical costs and hospitalisa-
tion rates associated with poorly controlled disease.
In conclusion, our meta-analysis demonstrated that
rapid inﬂiximab infusions are well tolerated in patients
who previously received at least three inﬂiximab infu-
sions of standard duration without an infusion reaction.
These data support consideration of widespread use of
1-h inﬂiximab infusions for selected patients who previ-
ously tolerated at least three to four standard duration
infusions. This may conserve valuable health care
resources and lead to improved adherence and quality of
life in patients already receiving inﬂiximab. Based on the
results of our study, a well-designed, high-quality pro-
spective randomised study may help provide a higher
level of evidence on which to base widespread institution
of rapid inﬂiximab infusion.
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